Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients.
M
M
Davidson
P D
PD
Harvey
R L
RL
Bergman
P
P
Powchik
R
R
Kaminsky
M F
MF
Losonczy
K L
KL
Davis
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D010919:Placebos; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D006220:Haloperidol